Illumina, Inc. is a global leader in DNA sequencing and array-based technologies used for genetic analysis in research, clinical, and applied markets. The company provides instruments, consumables, and informatics solutions that enable high-throughput sequencing and genomic data interpretation. Illumina’s platforms are widely used in oncology, reproductive health, population genomics, and other precision medicine applications.
Think of every patient as a unique garden: their genes are the soil, epigenetics is how the soil has been treated over time (fertilizer, pollution, stress), and the microbiome is the mix of plants and microbes living there. This work is about using data and models to understand how all three together affect health and how people respond to medicines, so treatments can be tailored to each person’s “garden” instead of using one-size-fits-all drugs.
Think of this as a super-powered microscope that doesn’t just look at cancer cells, but reads their genetic ‘instruction manual’. AI helps doctors quickly spot the tiny DNA changes that define each person’s cancer and match them with the best-targeted treatments.
This is about using very smart pattern-finding computers to read our genes and medical data so doctors can pick the right drug and dose for each person, instead of treating everyone the same.
Think of this as an AI co-pilot for genetic testing labs and clinicians: it reads huge DNA files, compares them to medical and genomic knowledge, and highlights which genetic changes are likely to matter for a patient’s disease and treatment options.